Modeling optimal cervical cancer prevention strategies in Nigeria

BMC Cancer

Nadia Demarteau¹  Imran O Morhason-Bello²  Babatunde Akinwunmi²  Isaac F Adewole² 

[1] Health Economics, Global Vaccines Development, GlaxoSmithKline Vaccines, Avenue Fleming 20 B-1300, Wavre, Belgium

[2] Department of Obstetrics & Gynaecology, College of Medicine, University of Ibadan/University College Hospital, Ibadan, Oyo State, Nigeria

关键词: Nigeria;    Africa;    Optimization model;    Human papillomavirus vaccination;    CC;   

Others  :  858793
DOI  :  10.1186/1471-2407-14-365

 received in 2013-10-10, accepted in 2014-05-15,  发布年份 2014

【 摘 要 】

Background

This study aims to assess the most efficient combinations of vaccination and screening coverage for the prevention of cervical cancer (CC) at different levels of expenditure in Nigeria.

Methods

An optimization procedure, using a linear programming approach and requiring the use of two models (an evaluation and an optimization model), was developed. The evaluation model, a Markov model, estimated the annual number of CC cases at steady state in a population of 100,000 women for four alternative strategies: screening only; vaccination only; screening and vaccination; and no prevention. The results of the Markov model for each scenario were used as inputs to the optimization model determining the optimal proportion of the population to receive screening and/or vaccination under different scenarios. The scenarios varied by available budget, maximum screening and vaccination coverage, and overall reachable population.

Results

In the base-case optimization model analyses, with a coverage constraint of 20% for one lifetime screening, 95% for vaccination and a budget constraint of $1 per woman per year to minimize CC incidence, the optimal mix of prevention strategies would result in a reduction of CC incidence of 31% (3-dose vaccination available) or 46% (2-dose vaccination available) compared with CC incidence pre-vaccination. With a 3-dose vaccination schedule, the optimal combination of the different strategies across the population would be 20% screening alone, 39% vaccination alone and 41% with no prevention, while with a 2-dose vaccination schedule the optimal combination would be 71% vaccination alone, and 29% with no prevention. Sensitivity analyses indicated that the results are sensitive to the constraints included in the optimization model as well as the cervical intraepithelial neoplasia (CIN) and CC treatment cost.

Conclusions

The results of the optimization model indicate that, in Nigeria, the most efficient allocation of a limited budget would be to invest in both vaccination and screening with a 3-dose vaccination schedule, and in vaccination alone before implementing a screening program with a 2-dose vaccination schedule.

【 授权许可】

   
2014 Demarteau et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
• [2]Antilla A, Aoki D, Arbyn M, Austoker J, Bosch X, Chirenje ZM, Cuzick J, Day NE, Denny LA, Fonn S, Franco E, Goldie SJ, Iftner T, Kricker A, Lawson H, Lynge E, Marett LD, McGoogan E, Meijer CJ, Miller AB, Patnick J, Robles SC, Ronco G, Schiffman MH, Sellors JW, Singer A, Suba EJ, Wright TC: Cervix Cancer Screening. Lyon: IARC Press; 2005.
• [3]Arbyn M, Raifu AO, Autier P, Ferlay J: Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007, 18:1708-1715.
• [4]Gustafsson L, Ponten J, Zack M, Adami HO: International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997, 8:755-763.
• [5]Symonds RP: Screening for cervical cancer: different problems in the developing and the developed world. Eur J Cancer Care (Engl) 1997, 6:275-279.
• [6]Adesina OA, Babarinsa IA, Fawole OA, Oladokun A, Adeniji AR, Adewole IF: Cervical cytology service in Nigeria: providers’ perspective. J Obstet Gynaecol 2003, 23:416-418.
• [7]Adewole IF, Benedet JL, Crain BT, Follen M: Evolving a strategic approach to cervical cancer control in Africa. Gynecol Oncol 2005, 99:S209-S212.
• [8]Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87:796-802.
• [9]Munoz N, Castellsagué X, Berrington de Gonzalez A, Gissmann L: Chapter 1. Human papillomavirus in the etiology of human cancer. Vaccine 2006, 24:S1-S10.
• [10]Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-9.
• [11]de Sanjosé S, Wim GQ, Laia A, Daan TG, Jo EK, Belen L, Tous S, Felix A, Bravo LE, Shin H, Vallejos CS, Alonso de Ruiz P, Lima MA, Guimera N, Clavero O, Alejo M, Llombart A, Cheng C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Hernandez Suarez GA, Estuardo Lombardi L, Banjo A, et al.: Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study [abstract]. Lancet Oncol 2010, 11:1048-1056.
• [12]Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GWK, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, et al.: Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women. J Natl Cancer Inst 2010, 102:325-339.
• [13]Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, et al.: The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16–26 years. J Infect Dis 2009, 199:926-935.
• [14]Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, Skinner SR, Apter D, Naud P, Salmeron J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De SP, Bosch FX, David MP, Descamps D, Struyf F, Dubin G: Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99.
• [15]Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Teixeira JC, Skinner SR, Jaisamrarn U, Limson G, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Harper DM, Huh W, Hardt K, Zahaf T, Descamps D, Struyf F, Dubin G, Lehtinen M: Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.
• [16]European Medicines Agency (EMA): Summary of product characteristics (Gardasil). [ http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp&mid=WC0b01ac058001d124 webcite] Date accessed: 2013
• [17]European Medicines Agency (EMA): Summary of product characteristics (Cervarix). [ http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000721/WC500024632.pdf webcite] Date accessed: 2014
• [18]Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, Schuind A, Descamps D: Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: Results from a randomized study. Hum Vaccin 2011, 7:1374-1386.
• [19]Romanowski B, Schwartz TF, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemans P, Catteau G, Descamps D: Immune response to the HPV-16/18 adjuvanted vaccine administered as a 2-dose or 3-dose schedule 2 years after vaccination. [Abstract n° SS 9-4]. In European Research Organisation on Genital Infection and Neoplasia (EUROGIN) Congress. Lisbon (Portugal); 2011.
• [20]Naud P, Roteli-Martins CM, De Carvalho N, Teixeira F, Borba P, Sanchez N, Zahaf T, Geeraerts B, Descamps D: HPV-16/18 vaccine: sustained immunogenicity and efficacy up to 9.4 years. [Abstract O-18.04]. In 27th International Papillomavirus Conference and Clinical Workshop. Berlin, Germany; 2011:153.
• [21]Aregay M, Shkedy Z, Molenberghs G, David MP, Tibaldi F: Model-Based Estimates of Long-Term Persistence of induced HPV Antibodies: a flexible subject-specific approach. J Biopharm Stat 2013, 23:1228-1248.
• [22]Earnshaw SR, Dennett SL: Integer/linear mathematical programming models: a tool for allocating healthcare resources. Pharmacoeconomics 2003, 21:839-851.
• [23]Earnshaw SR, Richter A, Sorensen SW, Hoerger TJ, Hicks KA, Engelgau M, Thompson T, Narayan KM, Williamson DF, Gregg E, Zhang P: Optimal allocation of resources across four interventions for type 2 diabetes. Med Decis Making 2002, 22:S80-S91.
• [24]Earnshaw SR, Hicks K, Richter A, Honeycutt A: A linear programming model for allocating HIV prevention funds with state agencies: a pilot study. Health Care Manag Sci 2007, 10:239-252.
• [25]Epstein DM, Chalabi Z, Claxton K, Sculpher M: Efficiency, equity, and budgetary policies: informing decisions using mathematical programming. Med Decis Making 2007, 27:128-137.
• [26]Richter A, Hicks KA, Earnshaw SR, Honeycutt AA: Allocating HIV prevention resources: a tool for state and local decision making. Health Policy 2008, 87:342-349.
• [27]Stinnett AA, Paltiel AD: Mathematical programming for the efficient allocation of health care resources. J Health Econ 1996, 15:641-653.
• [28]Weniger BG, Chen RT, Jacobson SH, Sewell EC, Deuson R, Livengood JR, Orenstein WA: Addressing the challenges to immunization practice with an economic algorithm for vaccine selection. Vaccine 1998, 16:1885-1897.
• [29]Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v2.0: Cancer incidence, mortality and prevalence worldwide: IARC CancerBase n° 10. [ http://globocan.iarc.fr webcite] Date accessed: 2013
• [30]Demarteau N, Breuer T, Standaert B: Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Pharmacoeconomics 2012, 30:337-353.
• [31]Colantonio L, Gómez JA, Demarteau N, Standaert B, Pichón-Rivière A, Augustovski F: Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. Vaccine 2009, 27:5519-5529.
• [32]Debicki D, Ferko N, Demarteau N, Gallivan S, Bauch C, Anonychuk A, Mantovani L, Capri S, Chou CY, Standaert B, Annemans L: Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination. Vaccine 2008, 26:F16-F28.
• [33]Suárez E, Smith JS, Bosch FX, Nieminen P, Chen CJ, Torvinen S, Demarteau N, Standaert B: Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. Vaccine 2008, 26:F29-F45.
• [34]Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, Oladepo O, Smith JS, Arslan A, Munoz N, Snijders PJ, Meijer CJ, Franceschi S: Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. Br J Cancer 2004, 90:638-645.
• [35]Harper D, Gall S, Naud P, Quint W, Dubin G, Jenkins D, Schuind A: Sustained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: Long-term follow-up through 6.4 years in women vaccinated with CervarixTM (GSK’s HPV 16/18 AS04 candidate vaccine). (Late-breaking abstracts presented for the Thirty-Ninth Annual Meeting of the Society of Gynecologic Oncologists, 9–12 Mar., Tampa, U.S.A.). Gynecol Oncol 2008, 109:158.
• [36]Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsagué X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
• [37]Institut Català d’Oncologia ICO: Information Centre on HPV and Cancer (HPV Information Centre). Date accessed: 2014
• [38]Skinner R, Apter D, Chow SN, Wheeler C, Dubin G: Cross-protection efficacy of Cervarix(tm) against oncogenic HPV types beyond HPV-16/18. [Abstract n° O-29.01]. In 25th International Papillomavirus Conference; 08–14. Malmö, Sweden; 2009.
• [39]Goldie SJ, Kim JJ, Kobus K, Goldhaber-Fiebert JD, Salomon J, O’Shea MKH, Xavier Bosch F, de Sanjosé S, Franco EL: Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 2007, 25:6257-6270.
• [40]National Bureau of Statistics: Consumer price index (base period November 2009 = 100). Abuja, Nigeria; 2012.
• [41]World Health Organisation (WHO): Life tables for WHO member states. Date accessed: 2010
• [42]Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L, Farhat S, Broering J, Darragh T, Palefsky J: Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001, 285:2995-3002.
• [43]Holowaty P, Miller AB, Rohan T, To T: Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999, 91:252-258.
• [44]Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP: Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998, 92:727-735.
• [45]Schlecht NF, Platt RW, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, Ferenczy A, Rohan TE, Villa LL, Franco EL: Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 2003, 95:1336-1343.
• [46]Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, Franco E: Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004, 96:604-615.
• [47]Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau MC, Desy M, Rohan TE: Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999, 180:1415-1423.
• [48]Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, Wright TC: Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005, 353:2158-2168.
• [49]McKenna C, Chalabi Z, Epstein D, Claxton K: Budgetary policies and available actions: a generalisation of decision rules for allocation and research decisions. J Health Econ 2010, 29:170-181.
• [50]Franco EL, Ferenczy A: Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination. Future Oncol 2007, 3:319-327.
• [51]Rogoza R, Ferko N, Bentley J, Meijer C, Berkhof J, Wang KL, Downs L, Smith J, Franco E: Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis --- OLD. Vaccine 2008. Submitted for publication